Generalized epilepsy with febrile seizures plus: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
No edit summary
Line 1: Line 1:
{{Infobox medical condition
| name = Generalized epilepsy with febrile seizures plus
| image = <!-- Image removed -->
| caption = <!-- Caption removed -->
| field = Neurology
| symptoms = Seizures, [[febrile seizures]]
| onset = Childhood
| duration = Varies
| causes = Genetic mutations
| risks = Family history
| diagnosis = Clinical evaluation, [[EEG]], genetic testing
| treatment = [[Antiepileptic drugs]], supportive care
}}
'''Generalized epilepsy with febrile seizures plus''' (GEFS+) is a [[genetic disorder]] characterized by a spectrum of [[epileptic seizures]] that begin in childhood. This condition is part of a group of disorders known as the [[genetic epilepsy with febrile seizures plus]] (GEFS+) spectrum.
'''Generalized epilepsy with febrile seizures plus''' (GEFS+) is a [[genetic disorder]] characterized by a spectrum of [[epileptic seizures]] that begin in childhood. This condition is part of a group of disorders known as the [[genetic epilepsy with febrile seizures plus]] (GEFS+) spectrum.



Revision as of 14:20, 29 December 2024

Generalized epilepsy with febrile seizures plus (GEFS+) is a genetic disorder characterized by a spectrum of epileptic seizures that begin in childhood. This condition is part of a group of disorders known as the genetic epilepsy with febrile seizures plus (GEFS+) spectrum.

Clinical Features

Individuals with GEFS+ experience a variety of seizure types, including febrile seizures, which are seizures associated with fever. These seizures typically occur in children between the ages of 6 months and 5 years. In addition to febrile seizures, affected individuals may experience other types of seizures, such as absence seizures, myoclonic seizures, and tonic-clonic seizures.

Genetic Basis

GEFS+ is caused by mutations in several genes, most commonly the SCN1A gene, which encodes a subunit of a sodium channel involved in the generation and propagation of action potentials in neurons. Other genes associated with GEFS+ include SCN1B, SCN2A, and GABRG2. These genetic mutations affect the normal function of ion channels, leading to increased neuronal excitability and seizures.

Diagnosis

The diagnosis of GEFS+ is based on clinical evaluation, family history, and electroencephalogram (EEG) findings. Genetic testing can confirm the diagnosis by identifying mutations in the associated genes. An EEG may show generalized spike-and-wave discharges, which are characteristic of generalized epilepsy.

Treatment

Treatment for GEFS+ typically involves the use of antiepileptic drugs (AEDs) to control seizures. The choice of medication depends on the specific type of seizures experienced by the individual. Commonly used AEDs include valproate, lamotrigine, and topiramate. In some cases, supportive care and lifestyle modifications, such as avoiding seizure triggers, may also be recommended.

Prognosis

The prognosis for individuals with GEFS+ varies. Some individuals may outgrow their seizures, while others may continue to experience seizures into adulthood. The severity and frequency of seizures can also vary widely among affected individuals.

See Also

References

<references group="" responsive="1"></references>


External Links